Faruqi & Faruqi, LLP Launches Investigation on Nutex Health Investor Claims
Faruqi & Faruqi, LLP, a prominent securities law firm based in New York, is actively investigating potential claims against Nutex Health Inc. (NASDAQ: NUTX) on behalf of its investors. James (Josh) Wilson, a partner at the firm, has reached out to investors who have incurred losses in Nutex Health after purchasing or acquiring securities between August 8, 2024, and August 15, 2025. The firm is reminding these investors to be mindful of the approaching deadline on October 21, 2025, which marks the last date for seeking the role of lead plaintiff in a federal securities class action against Nutex.
This investigation follows serious allegations detailed in a complaint asserting that Nutex and its executives breached federal securities laws by issuing false or misleading statements and concealing critical information from investors. Specific claims include that the company was engaged in a fraudulent scheme with its third-party vendor HaloMD, which purportedly executed a coordinated effort to defraud insurance companies. This resulted in unsustainable revenue attributed to Nutex's engagements with HaloMD, impacting its financial reporting and overall business prospects.
On July 22, 2025, Blue Orca Capital released a short report detailing these allegations, causing Nutex's share price to drop significantly, falling by 10.05% to close at $100.01 per share. A subsequent statement from Nutex expressed disagreement with the report's allegations but faced additional scrutiny when the company announced delays in filing its Form 10-Q for the quarter ending June 30, 2025. This delay, attributed to non-cash accounting adjustments regarding stock-based compensation obligations, further unsettled investors, leading to an additional 16.39% plunge in the stock price by August 15, 2025.
The lead plaintiff role is crucial, as it empowers an individual investor to act on behalf of all class members in the litigation. Any member of the class may nominate themselves to take this position or remain as an absent member without affecting their rights to any recovery. Furthermore, Faruqi & Faruqi encourages anyone with knowledge about Nutex's conduct, including whistleblowers, former employees, and shareholders, to share information with the firm. This outreach indicates the firm's commitment not only to helping current investors but also to ensuring that the truth regarding Nutex's practices comes to light.
In addition to its New York office, Faruqi & Faruqi has locations in Pennsylvania, California, and Georgia, representing a wide base of investors nationwide. Since its inception in 1995, the firm has successfully recovered hundreds of millions of dollars for investors, establishing a solid reputation in the realm of securities law.
For more information on the ongoing investigation and potential class action against Nutex Health, investors are encouraged to visit Faruqi & Faruqi's website. Interested parties may also directly contact partner Josh Wilson at 877-247-4292 or reach out at 212-983-9330 (Ext. 1310). With the legal landscape evolving, it is vital for affected investors to remain updated and proactive in their pursuit of justice and recovery for their financial losses.
This investigation follows serious allegations detailed in a complaint asserting that Nutex and its executives breached federal securities laws by issuing false or misleading statements and concealing critical information from investors. Specific claims include that the company was engaged in a fraudulent scheme with its third-party vendor HaloMD, which purportedly executed a coordinated effort to defraud insurance companies. This resulted in unsustainable revenue attributed to Nutex's engagements with HaloMD, impacting its financial reporting and overall business prospects.
On July 22, 2025, Blue Orca Capital released a short report detailing these allegations, causing Nutex's share price to drop significantly, falling by 10.05% to close at $100.01 per share. A subsequent statement from Nutex expressed disagreement with the report's allegations but faced additional scrutiny when the company announced delays in filing its Form 10-Q for the quarter ending June 30, 2025. This delay, attributed to non-cash accounting adjustments regarding stock-based compensation obligations, further unsettled investors, leading to an additional 16.39% plunge in the stock price by August 15, 2025.
The lead plaintiff role is crucial, as it empowers an individual investor to act on behalf of all class members in the litigation. Any member of the class may nominate themselves to take this position or remain as an absent member without affecting their rights to any recovery. Furthermore, Faruqi & Faruqi encourages anyone with knowledge about Nutex's conduct, including whistleblowers, former employees, and shareholders, to share information with the firm. This outreach indicates the firm's commitment not only to helping current investors but also to ensuring that the truth regarding Nutex's practices comes to light.
In addition to its New York office, Faruqi & Faruqi has locations in Pennsylvania, California, and Georgia, representing a wide base of investors nationwide. Since its inception in 1995, the firm has successfully recovered hundreds of millions of dollars for investors, establishing a solid reputation in the realm of securities law.
For more information on the ongoing investigation and potential class action against Nutex Health, investors are encouraged to visit Faruqi & Faruqi's website. Interested parties may also directly contact partner Josh Wilson at 877-247-4292 or reach out at 212-983-9330 (Ext. 1310). With the legal landscape evolving, it is vital for affected investors to remain updated and proactive in their pursuit of justice and recovery for their financial losses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.